STAT3 and neoplasm: WP1066, another STAT3 inhibitor in phase I clinical trial (ClinicalTrials.gov Identifier: NCT01904123), has been shown to directly enhance anti-tumor immunity by inhibiting TI-Treg function in mice bearing melanomas [85, 86].